Ciba Seeks FDA Clarification On Possible Triclosan “Data Gaps”
This article was originally published in The Rose Sheet
Executive Summary
Ciba Specialty Chemicals is seeking a meeting with FDA staff to discuss "outstanding issues" relating to triclosan safety, the company says in a recent letter to the agency
You may also be interested in...
FDA Will Consider Triclosan For OTC Acne Monograph Inclusion
FDA is seeking data on use of triclosan in topical acne treatment products, the agency announced in a Dec. 5 Federal Register 1notice
Non-Alcohol Antiseptic Hand Products Should Prove Efficacy – NDAC
Marketers of non-alcohol-based consumer antiseptic products should be required to prove their products provide clinical benefit prior to sale, an FDA advisory panel unanimously agreed Oct. 20
Triclosan Antigingivitis/Antiplaque Monograph Status Sought By Ciba
Ciba Specialty Chemicals requests that FDA include triclosan in its upcoming OTC monograph for antigingivitis/antiplaque oral care products in a recently-filed application